- Identified from 300 stage III gastric cancer patient’s resected specimens.
- Potentially effective for other tumors; lung, colorectal, breast, pancreatic cancer, etc.
- Companion diagnostic can be used.
Background and Technology
Gastric cancer (GC) is the second leading cause of cancer-related deaths worldwide. Although limited treatment options including antibodies targeting receptors of the growth factors and the immuno-checkpoint inhibitors are currently available for advanced gastric cancer, their response rates remain unsatisfactory. Thus novel anti-cancer agents with completely different mechanisms are indispensable for improvement of the treatment outcomes of GC patients.
Transmembrane Receptor-B has been identified via comprehensive transcriptome analysis of 300 resected tissues from stage III GC patients. Receptor-B was significantly expressed in specimens of patients with poor prognosis compared with five year survivors without recurrence.
- Intraperitoneal administration of monoclonal antibodies against Receptor-B significantly reduced tumor growth of human GC peritoneal dissemination model mice (fig).
- Patient’s cancer tissues were stained by Immunohistochemistry.
- Retrospective analysis by quantitative PCR data showed high predictive values to identify patients at risk of recurrences and poor prognosis.
- Tissue microarray data demonstrated cancer-specific overexpression of receptor-B in breast cancer, lung cancer, pancreatic cancer and colon cancer.
Dr. Mitsuro kanda Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, Japan.
We are looking for a company to license and develop this technology. Detailed data can be disclosed under CDA.